Systematic review and meta-analysis evaluates ML and DL models for diagnosing MASH and fibrosis
AI models help doctors spot liver disease with high accuracy
This systematic review and meta-analysis of 106 studies assessed machine learning (ML) and deep learning (DL) models for diagnosing metaboli…
New computer tools can diagnose fatty liver disease and scarring with impressive accuracy. This review analyzed data from many studies to se…
Review of scRNA-seq applications in non-alcoholic fatty liver disease and hepatocellular carcinoma research
New sequencing tools map liver disease across many species
This narrative review examines the use of single-cell and single-nucleus RNA sequencing in models of non-alcoholic fatty liver disease, fibr…
Scientists used advanced sequencing to study liver disease in humans and animals. This review maps how the disease changes at a cellular lev…
Review of liver disease immunomodulation strategies notes precision over broad suppression
Your Liver's Immune Cells Play Both Hero and Villain at Once
This narrative review examines immunomodulation approaches for liver diseases, including acute liver injury, HBV infection, MASLD/MASH, fibr…
Liver immune cells can both damage and repair your organ at the same time, a discovery that could unlock new precision treatments for hepati…
Phase 1/2a trial tests oral idebenone safety in adults with NASH and fibrosis
Can an oral drug help people with fatty liver disease? Early safety study begins
A randomized, double-blinded, placebo-controlled, single-center phase 1/2a study enrolled 53 adults with NASH and stage 1-3 fibrosis to asse…
A new oral drug for fatty liver disease has finished its early safety study, with results expected soon to show if it helps stop scarring.
Research across Cirrhosis
Related studies from across the Cirrhosis family.
Narrative review explores macrophage reprogramming for liver fibrosis and MASH
Scientists explore new ways to reprogram liver cells to heal damaged tissue and stop scarring
This narrative review summarizes macrophage reprogramming strategies for liver fibrosis and MASH. Approaches include gene modulation, pharma…
A recent review looks at fresh methods to change how liver immune cells behave. These changes could help heal liver scarring and improve hea…
PON1 genetic variants rs2057681 and rs854572 modulate PONase activity and dysmetabolic risk in MASLD
Your Liver's Hidden Genetic Shield
This cohort study of 922 Portuguese individuals from the PREVADIAB2 cohort examined associations between PON1 genetic variants and metabolic…
Your specific DNA pattern for a liver enzyme predicts diabetes and liver scarring risk better than simple blood tests alone.
Review of bile acid homeostasis regulation in liver disease and cancer
Review of bile acid regulation for liver disease conditions shows limited evidence
This narrative review examines the regulation of bile acids homeostasis in conditions including cholestasis, hepatic fibrosis, cirrhosis, he…
Bile acid imbalance drives liver disease, but this review found no data proving that regulating it safely treats conditions like cirrhosis o…
Hospitalized malignant neoplasm patients show high comorbidity burden and distinct disease patterns across 163 Chinese hospitals
Hospitalized cancer patients in China often have other serious health conditions
This retrospective cohort study examined 107,029 hospitalized patients with malignant neoplasms across 163 hospitals in Zhanjiang, China.
Hospitalized cancer patients in China often face five other serious health conditions, with rural residents, men, and those aged 65 or older…
Perspective reviews emerging antifibrotic therapies for metabolic dysfunction-associated steatohepatitis
Could new drugs finally treat the liver scarring of MASH?
A perspective article reviews emerging antifibrotic therapies for metabolic dysfunction-associated steatohepatitis (MASH), including metabol…
New metabolic drugs and direct liver therapies offer fresh hope for reversing the scarring that leads to dangerous cirrhosis in MASH patient…
Questions about Fibrosis
How does single-nucleus RNA sequencing apply to fibrosis research?
Single-nucleus RNA sequencing helps researchers map specific cell types and gene networks that drive fibrosis in the liver and kidneys, revealing how healthy repair fails and how to target it.
Full answer →What stage of fibrosis can be treated in the idebenone trial?
The idebenone trial specifically targets patients with non-alcoholic steatohepatitis who have stage 1, 2, or 3 fibrosis.
Full answer →Are there new immunomodulation strategies to treat liver fibrosis?
Yes, new immunomodulation strategies for liver fibrosis focus on reprogramming macrophages, targeting specific immune subsets, and using metabolic therapies like GLP-1 analogues and THRβ activators.
Full answer →Can single-cell RNA sequencing help understand fibrosis in fatty liver disease?
Single-cell RNA sequencing helps map specific immune cells and communication networks that drive fibrosis in fatty liver disease, revealing new targets for treatment.
Full answer →